UB Paderborn / Katalog / Suche / in CDI

Modification of Nuclear PML Protein by SUMO-1 Regulates Fas-Induced Apoptosis in Rheumatoid Arthritis Synovial Fibroblasts

Proceedings of the National Academy of Sciences - PNAS, 2007-03, Vol.104 (12), p.5073-5078

2007

Volltextzugriff (PDF)

Validity and score interpretation of the 12-item Psoriatic Arthritis Impact of Disease: an analysis of pooled data from two phase 3 trials of bimekizumab in patients with psoriatic arthritis

Rheumatic & musculoskeletal diseases open, 2024-01, Vol.10 (1), p.e003548

2024

Volltextzugriff (PDF)

Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITAL

Rheumatic & musculoskeletal diseases open, 2024-02, Vol.10 (1), p.e003855

2024

Volltextzugriff (PDF)

NEDP1, a Highly Conserved Cysteine Protease That deNEDDylates Cullins

The Journal of biological chemistry, 2003-07, Vol.278 (28), p.25637-25643

2003

Volltextzugriff (PDF)

51569 Bimekizumab treatment resulted in sustained improvements in nail psoriasis and signs and symptoms of psoriatic arthritis in patients with baseline nail disease: 1-year pooled results from two phase 3 studies

Journal of the American Academy of Dermatology, 2024-09, Vol.91 (3), p.AB145-AB145

2024

Volltextzugriff (PDF)

Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL)

The Lancet (British edition), 2023-01, Vol.401 (10370), p.25-37

2023

Volltextzugriff (PDF)

51609 Bimekizumab treatment resulted in sustained improvements in pain and fatigue in patients with active psoriatic arthritis and baseline psoriasis: 1-year results from two phase 3 studies

Journal of the American Academy of Dermatology, 2024-09, Vol.91 (3), p.AB24-AB24

2024

Volltextzugriff (PDF)

51558 Bimekizumab treatment resulted in rapid and sustained improvement in total and individual Bath Ankylosing Spondylitis Disease Activity Index components in patients with psoriatic arthritis: 1-year results from two phase 3 studies

Journal of the American Academy of Dermatology, 2024-09, Vol.91 (3), p.AB24-AB24

2024

Volltextzugriff (PDF)

P171 Bimekizumab in bDMARD-naïve patients with active psoriatic arthritis: improvements in PsARC over 24 weeks in the Phase 3 BE OPTIMAL trial

Rheumatology (Oxford, England), 2023-04, Vol.62 (Supplement_2)

2023

Volltextzugriff (PDF)

P189 Bimekizumab in patients with psoriatic arthritis with prior inadequate response to TNF inhibitors: improvements of PsARC over 16 weeks in the Phase 3 BE COMPLETE trial

Rheumatology (Oxford, England), 2023-04, Vol.62 (Supplement_2)

2023

Volltextzugriff (PDF)

Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial

The Lancet (British edition), 2020-02, Vol.395 (10222), p.427-440

2020

Volltextzugriff (PDF)

Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE)

The Lancet (British edition), 2023-01, Vol.401 (10370), p.38-48

2023

Volltextzugriff (PDF)

P171 Bimekizumab impact on core group for research and assessment of psoriasis and psoriatic arthritis domains for patients with psoriatic arthritis: 52-week results from four phase 3 studies

Rheumatology (Oxford, England), 2024-04, Vol.63 (Supplement_1)

2024

Volltextzugriff (PDF)

E070 Sustained and consistent efficacy of bimekizumab in patients with active psoriatic arthritis regardless of prior TNF-inhibitor status: results from the phase 3 BE OPTIMAL and BE COMPLETE trials

Rheumatology (Oxford, England), 2024-04, Vol.63 (Supplement_1)

2024

Volltextzugriff (PDF)

E069 Bimekizumab maintained efficacy responses through 52 weeks in patients with psoriatic arthritis and inadequate response or intolerance to tumour necrosis factor inhibitors who were responders at week 16: results from a phase 3, randomised study

Rheumatology (Oxford, England), 2024-04, Vol.63 (Supplement_1)

2024

Volltextzugriff (PDF)

E067 Bimekizumab maintained efficacy responses through 52 weeks in biologic disease-modifying antirheumatic drugnaïve patients with psoriatic arthritis who were responders at week 16: results from BE OPTIMAL, a phase 3, activereference study

Rheumatology (Oxford, England), 2024-04, Vol.63 (Supplement_1)

2024

Volltextzugriff (PDF)

43024 Bimekizumab improves joint measures in patients with active psoriatic arthritis and moderate or severe psoriasis: Pooled 16-week results from phase 3 randomized, placebo-controlled studies BE OPTIMAL and BE COMPLETE

Journal of the American Academy of Dermatology, 2023-09, Vol.89 (3), p.AB128-AB128

2023

Volltextzugriff (PDF)

43744 Bimekizumab in bDMARD-naïve patients with psoriatic arthritis and skin involvement: Analysis of radiographic progression at Week 16 of BE OPTIMAL, a phase 3, multicenter, randomized, placebo- controlled, active reference study

Journal of the American Academy of Dermatology, 2023-09, Vol.89 (3), p.AB128-AB128

2023

Volltextzugriff (PDF)

Safety and Efficacy of Bimekizumab in Patients With Active Psoriatic Arthritis: Three‐Year Results From a Phase IIb Randomized Controlled Trial and Its Open‐Label Extension Study

Arthritis & rheumatology (Hoboken, N.J.), 2022-12, Vol.74 (12), p.1959-1970

2022

Volltextzugriff (PDF)

Effect of bimekizumab on symptoms and impact of disease in patients with psoriatic arthritis over 3 years: results from BE ACTIVE

Rheumatology, 2023-02, Vol.62 (2), p.617-628

2023

Volltextzugriff (PDF)

32937 Bimekizumab treatment response is maintained up to 3 years in patients with psoriatic arthritis: Responder analyses from BE ACTIVE, a phase 2b dose-ranging study, and its open-label extension

Journal of the American Academy of Dermatology, 2022-09, Vol.87 (3), p.AB146-AB146

2022

Volltextzugriff (PDF)

Effect of Bimekizumab on Patient-Reported Disease Impact in Patients with Psoriatic Arthritis: 1-Year Results from Two Phase 3 Studies

Rheumatology, 2024-05, Vol.63 (9), p.2399-2410

2024

Volltextzugriff (PDF)

Bimekizumab treatment in biologic DMARD-naïve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase III, randomised, placebo-controlled, active reference BE OPTIMAL study

Annals of the rheumatic diseases, 2023-11, Vol.82 (11), p.1404

2023

Volltextzugriff (PDF)

OA36 Bimekizumab in patients with psoriatic arthritis: achievement and maintenance of Psoriatic Arthritis Response Criteria responses through 3 years in a phase 2b open-label extension study

Rheumatology (Oxford, England), 2022-04, Vol.61 (Supplement_1)

2022

Volltextzugriff (PDF)

First-in-human phase 1 study of the PARP/tankyrase inhibitor 2X-121 (E7449) as monotherapy in patients with advanced solid tumors and validation of a novel drug response predictor (DRP) mRNA biomarker

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.2505-2505

2018

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Modification of Nuclear PML Protein by SUMO-1 Regulates Fas-Induced Apoptosis in Rheumatoid Arthritis Synovial Fibroblasts

Validity and score interpretation of the 12-item Psoriatic Arthritis Impact of Disease: an analysis of pooled data from two phase 3 trials of bimekizumab in patients with psoriatic arthritis

Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITAL

NEDP1, a Highly Conserved Cysteine Protease That deNEDDylates Cullins

51569 Bimekizumab treatment resulted in sustained improvements in nail psoriasis and signs and symptoms of psoriatic arthritis in patients with baseline nail disease: 1-year pooled results from two phase 3 studies

Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL)

51609 Bimekizumab treatment resulted in sustained improvements in pain and fatigue in patients with active psoriatic arthritis and baseline psoriasis: 1-year results from two phase 3 studies

51558 Bimekizumab treatment resulted in rapid and sustained improvement in total and individual Bath Ankylosing Spondylitis Disease Activity Index components in patients with psoriatic arthritis: 1-year results from two phase 3 studies

P171 Bimekizumab in bDMARD-naïve patients with active psoriatic arthritis: improvements in PsARC over 24 weeks in the Phase 3 BE OPTIMAL trial

P189 Bimekizumab in patients with psoriatic arthritis with prior inadequate response to TNF inhibitors: improvements of PsARC over 16 weeks in the Phase 3 BE COMPLETE trial

Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial

Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE)

P171 Bimekizumab impact on core group for research and assessment of psoriasis and psoriatic arthritis domains for patients with psoriatic arthritis: 52-week results from four phase 3 studies

E070 Sustained and consistent efficacy of bimekizumab in patients with active psoriatic arthritis regardless of prior TNF-inhibitor status: results from the phase 3 BE OPTIMAL and BE COMPLETE trials

E069 Bimekizumab maintained efficacy responses through 52 weeks in patients with psoriatic arthritis and inadequate response or intolerance to tumour necrosis factor inhibitors who were responders at week 16: results from a phase 3, randomised study

E067 Bimekizumab maintained efficacy responses through 52 weeks in biologic disease-modifying antirheumatic drugnaïve patients with psoriatic arthritis who were responders at week 16: results from BE OPTIMAL, a phase 3, activereference study

43024 Bimekizumab improves joint measures in patients with active psoriatic arthritis and moderate or severe psoriasis: Pooled 16-week results from phase 3 randomized, placebo-controlled studies BE OPTIMAL and BE COMPLETE

43744 Bimekizumab in bDMARD-naïve patients with psoriatic arthritis and skin involvement: Analysis of radiographic progression at Week 16 of BE OPTIMAL, a phase 3, multicenter, randomized, placebo- controlled, active reference study

Safety and Efficacy of Bimekizumab in Patients With Active Psoriatic Arthritis: Three‐Year Results From a Phase IIb Randomized Controlled Trial and Its Open‐Label Extension Study

Effect of bimekizumab on symptoms and impact of disease in patients with psoriatic arthritis over 3 years: results from BE ACTIVE

32937 Bimekizumab treatment response is maintained up to 3 years in patients with psoriatic arthritis: Responder analyses from BE ACTIVE, a phase 2b dose-ranging study, and its open-label extension

Effect of Bimekizumab on Patient-Reported Disease Impact in Patients with Psoriatic Arthritis: 1-Year Results from Two Phase 3 Studies

Bimekizumab treatment in biologic DMARD-naïve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase III, randomised, placebo-controlled, active reference BE OPTIMAL study

OA36 Bimekizumab in patients with psoriatic arthritis: achievement and maintenance of Psoriatic Arthritis Response Criteria responses through 3 years in a phase 2b open-label extension study

First-in-human phase 1 study of the PARP/tankyrase inhibitor 2X-121 (E7449) as monotherapy in patients with advanced solid tumors and validation of a novel drug response predictor (DRP) mRNA biomarker

Suchergebnisse filtern